Strs Ohio Makes New Investment in Halozyme Therapeutics, Inc. $HALO

Strs Ohio acquired a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 30,000 shares of the biopharmaceutical company's stock, valued at approximately $1,914,000.

Several other large investors have also recently bought and sold shares of the business. Isthmus Partners LLC raised its position in Halozyme Therapeutics by 2.5% in the first quarter. Isthmus Partners LLC now owns 6,875 shares of the biopharmaceutical company's stock worth $439,000 after acquiring an additional 169 shares in the last quarter. OneDigital Investment Advisors LLC increased its position in shares of Halozyme Therapeutics by 1.7% in the first quarter. OneDigital Investment Advisors LLC now owns 10,176 shares of the biopharmaceutical company's stock valued at $649,000 after buying an additional 175 shares in the last quarter. Park Place Capital Corp increased its position in shares of Halozyme Therapeutics by 20.1% in the first quarter. Park Place Capital Corp now owns 1,086 shares of the biopharmaceutical company's stock valued at $69,000 after buying an additional 182 shares in the last quarter. Xponance Inc. increased its position in shares of Halozyme Therapeutics by 1.1% in the first quarter. Xponance Inc. now owns 18,652 shares of the biopharmaceutical company's stock valued at $1,190,000 after buying an additional 198 shares in the last quarter. Finally, Bessemer Group Inc. increased its position in shares of Halozyme Therapeutics by 62.9% in the first quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company's stock valued at $34,000 after buying an additional 207 shares in the last quarter. Hedge funds and other institutional investors own 97.79% of the company's stock.

Halozyme Therapeutics Stock Performance

NASDAQ HALO opened at $75.85 on Wednesday. The firm has a market capitalization of $8.87 billion, a P/E ratio of 17.36, a P/E/G ratio of 0.42 and a beta of 1.19. Halozyme Therapeutics, Inc. has a 1-year low of $42.01 and a 1-year high of $77.60. The company has a debt-to-equity ratio of 4.54, a current ratio of 8.36 and a quick ratio of 7.01. The business's 50-day simple moving average is $65.95 and its 200-day simple moving average is $60.71.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 EPS for the quarter, beating the consensus estimate of $1.23 by $0.31. The business had revenue of $325.72 million for the quarter, compared to the consensus estimate of $282.66 million. Halozyme Therapeutics had a return on equity of 150.85% and a net margin of 47.28%.The company's revenue was up 40.8% on a year-over-year basis. During the same period last year, the business posted $0.91 EPS. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. Equities analysts predict that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Insiders Place Their Bets

In other Halozyme Therapeutics news, CFO Nicole Labrosse sold 20,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Wednesday, September 10th. The stock was sold at an average price of $75.71, for a total transaction of $1,514,200.00. Following the sale, the chief financial officer directly owned 24,306 shares in the company, valued at $1,840,207.26. The trade was a 45.14% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Wednesday, September 3rd. The stock was sold at an average price of $74.44, for a total value of $1,488,800.00. Following the sale, the chief executive officer owned 733,719 shares in the company, valued at $54,618,042.36. This represents a 2.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 124,000 shares of company stock worth $7,830,320 in the last three months. 2.90% of the stock is owned by insiders.

Analyst Ratings Changes

A number of brokerages have recently weighed in on HALO. The Goldman Sachs Group began coverage on Halozyme Therapeutics in a research report on Thursday, July 10th. They issued a "neutral" rating and a $55.00 price target for the company. JPMorgan Chase & Co. raised their price target on Halozyme Therapeutics from $60.00 to $63.00 and gave the company a "neutral" rating in a research report on Thursday, August 7th. JMP Securities increased their price objective on Halozyme Therapeutics from $78.00 to $91.00 and gave the company a "market outperform" rating in a research note on Wednesday, August 6th. Morgan Stanley increased their price objective on Halozyme Therapeutics from $75.00 to $80.00 and gave the company an "overweight" rating in a research note on Monday, August 18th. Finally, Wall Street Zen lowered Halozyme Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Friday, September 5th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $67.11.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.